SCHEMBL3007745

SCHEMBL3007745

O=S(=O)(c1cccc(Cl)c1Cl)N1CCN(c2nc(Cc3cc(Cl)cc(Cl)c3)cs2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.44
KMT2A Q03164 5/20 0.42
MAPT P10636 5/20 0.42
LMNA P02545 4/20 0.42
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
CHRM1 P11229 1/20 0.39
POLB P06746 1/20 0.38
MAPK1 P28482 2/20 0.38
HTR6 P50406 1/20 0.37
CHRM4 P08173 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999233 0.93 SMN1; SMN2 (0.45) TSHRKMT2AMAPTLMNAALDH1A1
SCHEMBL3008268 0.92 CHRM4 (0.45) KMT2AMAPTLMNAALDH1A1MEN1
SCHEMBL3006926 0.91 TSHR (0.45) TSHRKMT2AMAPTLMNAALDH1A1
SCHEMBL3017663 0.90 KMT2A (0.47) TSHRKMT2AMAPTLMNAALDH1A1
SCHEMBL3005306 0.90 TSHR (0.43) TSHRKMT2AMAPTLMNAALDH1A1
SCHEMBL3018936 0.90 TSHR (0.46) TSHRKMT2AMAPTLMNAALDH1A1
SCHEMBL3004891 0.89 TSHR (0.42) TSHRKMT2AMAPTLMNAALDH1A1
SCHEMBL3014026 0.89 TSHR (0.44) TSHRKMT2AMAPTLMNAALDH1A1
SCHEMBL3015125 0.89 LMNA (0.44) TSHRKMT2AMAPTLMNAALDH1A1
SCHEMBL3016580 0.89 KMT2A (0.44) TSHRKMT2AMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TSHR 3320/4885KMT2A 2680/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.